Novalis LifeSciences
Description
Novalis LifeSciences is a prominent venture capital firm headquartered in Hampton, New Hampshire, with a dedicated focus on breakthrough technologies across the life sciences sector. Established in 2017, the firm strategically invests in companies developing innovative solutions in biotechnology, pharmaceuticals, diagnostics, and medical technology. Their mission revolves around identifying and nurturing early to growth-stage companies that have the potential to significantly impact human health and scientific advancement.
The firm employs a flexible investment strategy, engaging with companies from seed to growth equity stages. Novalis LifeSciences is known for often taking a lead or co-lead position in funding rounds, demonstrating a deep commitment to its portfolio companies. Their typical initial investment ranges from $5 million to $25 million, reflecting their capacity to support substantial development and commercialization efforts. Beyond capital, Novalis provides strategic guidance and operational expertise, leveraging its team's extensive industry experience to help portfolio companies navigate complex scientific and market challenges.
Novalis LifeSciences has successfully raised significant capital to fuel its investment activities. The firm closed its inaugural fund, Novalis LifeSciences Fund I, with $85 million in commitments in 2019. Building on this success, they announced the closing of their second and substantially larger fund, Novalis LifeSciences Fund II, in April 2023, raising $300 million. This increased capital base allows Novalis to scale its investment activities, support a broader range of companies, and participate more robustly in follow-on rounds, ensuring sustained growth for its portfolio.
Investor Profile
Novalis LifeSciences has backed more than 20 startups, with 0 new investments in the last 12 months alone. The firm has led 13 rounds, about 65% of its total and boasts 4 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series C, Series D rounds (top funding stages).
- Majority of deals are located in United States, Belgium, The Netherlands.
- Strong thematic focus on Biotechnology, Health Care, Therapeutics.
- Typical check size: $5M – $25M.
Stage Focus
- Series B (40%)
- Series C (15%)
- Series D (15%)
- Post Ipo Equity (10%)
- Series Unknown (10%)
- Series A (5%)
- Seed (5%)
Country Focus
- United States (80%)
- Belgium (10%)
- The Netherlands (5%)
- United Kingdom (5%)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
Industry Focus
- Biotechnology
- Health Care
- Therapeutics
- Analytics
- Life Science
- Medical Device
- Agriculture
- Health Diagnostics
- Agtech
- Chemical
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
